IP-001 with ablation for colorectal liver metastases
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the drug IP-001 to tumor ablation (microwave or irreversible electroporation) helps control colorectal cancer that has spread to the liver. The goal is to find the best dose and see how the immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to the liver and can be measured on scans.
- You are 18 years or older.
- Your overall health status is good (ECOG 0 or 1).
- Your liver, kidneys, and bone marrow are working well enough based on blood tests.
- You are willing and able to give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
This trial tests a treatment that uses tiny electric pulses to destroy liver tumors (NanoKnife) combined with immunotherapy to boost your immune system against cancer. It's for people with colorectal cancer that has spread to the liver and hasn't responded enough to chemotherapy.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.